Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer

Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1987-02, Vol.294 (6570), p.467-469
Main Authors: Cantwell, B M, Harris, A L
Format: Article
Language:English
Subjects:
Adult
Aged
Breast cancer
Calcium
Clinical Research
Corticosteroids
Diphosphonates
Diphosphonates - therapeutic use
Dosage
Female
Humans
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Intravenous infusions
Lung neoplasms
Male
Middle Aged
Neoplasms - complications
Oncology
Oral rehydration
Pamidronate
Serum albumins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The serum calcium concentrations decreased significantly after treatment with aminohydroxypropylidene diphosphonate. Ten patients became normocalcaemic (normal range, adjusted for serum albumin, 2.25-2.75 mmol/l), two became hypocalcaemic, three showed decreases in serum calcium concentrations of more than 0.75 mmol/l, and one showed a decrease of more than 0.55 mmol/l. Only one patient had a minimum concentration greater than 2.77 mmol/l. Aminohydroxypropylidene diphosphonate was effective in metastatic and non-metastatic hypercalcaemia, and its hypocalcaemic effect was prolonged in some cases. There were no appreciable side effects. Single high dose infusions of aminohydroxypropylidene diphosphonate could replace conventional daily lower dose infusions, but the optimum frequency of high dose infusions remains to be determined.
ISSN:0267-0623
0959-8138
1468-5833
DOI:10.1136/bmj.294.6570.467